Guerbet S. A. Total Assets
Guerbet S. A. total assets. Based on the latest financial reports, Guerbet S. A. (GBT) holds total assets worth €930.02 Million EUR (≈ $1.09 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Guerbet S. A. (GBT) total market value for the company's overall valuation and market capitalisation.
Total Assets of Guerbet S. A. (2004–2025)
Total assets of Guerbet S. A. from 2004 to 2025. This chart illustrates how Guerbet S. A.'s total assets have evolved over time, based on quarterly financial data. See Guerbet S. A. share price for real-time trading data and today's change.
Guerbet S. A. - Asset Composition Analysis
Guerbet S. A. Total Assets Breakdown (December 2025)
Guerbet S. A. total assets breakdown as of December 2025. Guerbet S. A.'s total assets of €930.02 Million consist of 64.6% current assets and 35.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 12.4% |
| Accounts Receivable | €173.66 Million | 18.7% |
| Inventory | €296.37 Million | 31.9% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €32.76 Million | 3.5% |
| Goodwill | €28.77 Million | 3.1% |
Asset Composition Trend (2004–2025)
This chart illustrates how Guerbet S. A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore GBT working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Guerbet S. A.'s current assets represent 64.6% of total assets in 2025, an increase from 60.6% in 2004.
- Cash Position: Cash and equivalents constituted 12.4% of total assets in 2025, up from 4.8% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, a decrease from 10.0% in 2004.
- Asset Diversification: The largest asset category is inventory at 31.9% of total assets.
Guerbet S. A. Competitors by Total Assets
Key competitors of Guerbet S. A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Shanghai Sanyou Medical Co Ltd
SHG:688085
|
China | CN¥2.34 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥988.48 Million |
|
PULSION Medical Systems SE
MU:PUS
|
Germany | €35.15 Million |
|
Cleo Diagnostics Ltd
AU:COV
|
Australia | AU$9.96 Million |
|
Memphasys Ltd
AU:MEM
|
Australia | AU$10.45 Million |
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
Guerbet S. A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.49 | 2.32 | 2.34 |
| Quick Ratio | 1.26 | 1.12 | 1.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €359.47 Million | €335.48 Million | €268.34 Million |
Guerbet S. A. - Advanced Valuation Insights
This section examines the relationship between Guerbet S. A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.35 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | -10.3% |
| Total Assets | €930.02 Million |
| Market Capitalization | $93.47 Million USD |
Valuation Analysis
Below Book Valuation: The market values Guerbet S. A.'s assets below their book value (0.10x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Guerbet S. A.'s assets decreased by 10.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Guerbet S. A. (2004–2025)
The table below shows the annual total assets of Guerbet S. A. from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €930.02 Million ≈ $1.09 Billion |
-10.34% |
| 2024-12-31 | €1.04 Billion ≈ $1.21 Billion |
+1.17% |
| 2023-12-31 | €1.03 Billion ≈ $1.20 Billion |
+9.11% |
| 2022-12-31 | €939.64 Million ≈ $1.10 Billion |
-6.11% |
| 2021-12-31 | €1.00 Billion ≈ $1.17 Billion |
+5.83% |
| 2020-12-31 | €945.71 Million ≈ $1.11 Billion |
-6.26% |
| 2019-12-31 | €1.01 Billion ≈ $1.18 Billion |
-6.66% |
| 2018-12-31 | €1.08 Billion ≈ $1.26 Billion |
+13.34% |
| 2017-12-31 | €953.59 Million ≈ $1.11 Billion |
-7.25% |
| 2016-12-31 | €1.03 Billion ≈ $1.20 Billion |
+13.92% |
| 2015-12-31 | €902.50 Million ≈ $1.06 Billion |
+89.75% |
| 2014-12-31 | €475.63 Million ≈ $556.07 Million |
+3.50% |
| 2013-12-31 | €459.55 Million ≈ $537.26 Million |
-0.31% |
| 2012-12-31 | €460.97 Million ≈ $538.92 Million |
+2.50% |
| 2011-12-31 | €449.72 Million ≈ $525.77 Million |
+6.57% |
| 2010-12-31 | €422.01 Million ≈ $493.37 Million |
+7.02% |
| 2009-12-31 | €394.32 Million ≈ $461.00 Million |
+2.97% |
| 2008-12-31 | €382.96 Million ≈ $447.72 Million |
+7.21% |
| 2007-12-31 | €357.21 Million ≈ $417.62 Million |
+9.40% |
| 2006-12-31 | €326.51 Million ≈ $381.72 Million |
+10.38% |
| 2005-12-31 | €295.81 Million ≈ $345.84 Million |
+15.70% |
| 2004-12-31 | €255.67 Million ≈ $298.91 Million |
-- |
About Guerbet S. A.
Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconne… Read more